SLRX vs. TCRT, ADXS, MBIO, ENSC, IMCC, INDP, SNOA, MTNB, DRMA, and CNSP
Should you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include Alaunos Therapeutics (TCRT), Ayala Pharmaceuticals (ADXS), Mustang Bio (MBIO), Ensysce Biosciences (ENSC), IM Cannabis (IMCC), Indaptus Therapeutics (INDP), Sonoma Pharmaceuticals (SNOA), Matinas Biopharma (MTNB), Dermata Therapeutics (DRMA), and CNS Pharmaceuticals (CNSP). These companies are all part of the "pharmaceutical products" industry.
Salarius Pharmaceuticals vs. Its Competitors
Salarius Pharmaceuticals (NASDAQ:SLRX) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and earnings.
Salarius Pharmaceuticals has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -1.08, suggesting that its share price is 208% less volatile than the S&P 500.
Alaunos Therapeutics has higher revenue and earnings than Salarius Pharmaceuticals.
Alaunos Therapeutics' return on equity of -169.30% beat Salarius Pharmaceuticals' return on equity.
11.9% of Salarius Pharmaceuticals shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 1.2% of Salarius Pharmaceuticals shares are held by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Salarius Pharmaceuticals received 19 more outperform votes than Alaunos Therapeutics when rated by MarketBeat users. However, 58.33% of users gave Alaunos Therapeutics an outperform vote while only 54.17% of users gave Salarius Pharmaceuticals an outperform vote.
In the previous week, Salarius Pharmaceuticals and Salarius Pharmaceuticals both had 2 articles in the media. Salarius Pharmaceuticals' average media sentiment score of 0.25 beat Alaunos Therapeutics' score of 0.00 indicating that Salarius Pharmaceuticals is being referred to more favorably in the media.
Summary
Alaunos Therapeutics beats Salarius Pharmaceuticals on 7 of the 10 factors compared between the two stocks.
Get Salarius Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Salarius Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SLRX) was last updated on 6/23/2025 by MarketBeat.com Staff
Buy SLRX Stock Free SLRX Stock Alerts